Trial Profile
Phase I Study of High Dose Gefitinib (Iressa) for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 29 Jan 2018 Status changed from active, no longer recruiting to completed.
- 20 Oct 2014 Planned End Date changed from 1 Dec 2012 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
- 20 Oct 2014 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.